Physician profile
John Manchin
NPI 1134231640
$15,959.70
in general payments reported to CMS, 2019-2025
63 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,813 · 2020: $2,413 · 2021: $3,024 · 2022: $2,485 · 2023: $2,026 · 2024: $2,498 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,070 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,069.59 |
| Education | $155.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,482.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,708.33 | 2019-2025 | Farxiga, Brilinta, Airsupra |
| Novo Nordisk INC | $1,621.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $937.76 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $928.51 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $699.43 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $584.93 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $554.63 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $460.12 | 2019-2021 | |
| Glaxosmithkline, LLC. | $409.77 | 2019-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $402.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $380.28 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $368.44 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $343.49 | 2019-2024 | Spravato |
| Shield Therapeutics INC | $333.51 | 2023-2025 | Accrufer |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Manchin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.